Welcome to our dedicated page for NewAmsterdam Pharma Company N.V SEC filings (Ticker: NAMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NewAmsterdam Pharma Company N.V. filings document a late-stage clinical biopharmaceutical issuer developing oral, non-statin therapies for cardiovascular-risk patients with elevated LDL-C. Its Form 8-K reports furnish financial results, corporate updates, investor presentations and clinical-program disclosures involving obicetrapib, including its use alone and with ezetimibe.
The company’s SEC record also covers proxy governance, executive compensation, equity awards, director and officer matters, compensatory arrangements and Nasdaq-listed securities. Cover-page disclosures identify ordinary shares under NAMS and warrants under NAMSW, while material-event filings record Regulation FD presentations, leadership-related agreements and public-company capital-structure information.
NewAmsterdam Pharma Company N.V. reports that Chief Accounting Officer Louise Kooij will end her employment effective August 31, 2026. The company and Ms. Kooij entered into a separation agreement on April 24, 2026.
Under this agreement, she is eligible for a lump-sum payment equal to twelve months of her current base salary, a pro-rated 2026 annual cash bonus based on target achievement through the separation date, and payment for accrued but unused holiday and vacation days in line with Dutch law.
The company will extend vesting of her outstanding stock options and RSU awards through January 10, 2027, and vested stock options will remain exercisable until February 10, 2027. The agreement also includes confidentiality, non-compete and non-disparagement covenants and a release of claims, and is expected to be filed with the company’s Form 10-Q for the quarter ending June 30, 2026.
NewAmsterdam Pharma Company N.V. is soliciting proxies for its 2026 Annual General Meeting to be held on June 2, 2026 at 5:00 p.m. CEST in Amsterdam. The agenda includes adoption of the Dutch statutory annual accounts for the fiscal year ended December 31, 2025, discharge of directors, auditor instruction and ratification, director reappointments, extensions of authorizations to issue ordinary shares and to limit pre-emption rights, approval of a 2026 Employee Stock Purchase Plan (ESPP) reserving 1,150,000 ordinary shares, and a non-binding advisory vote on 2025 executive compensation.
The Record Date is May 5, 2026; Beneficial Owners must submit an Attendance Notice and supporting proof by 11:59 p.m. ET on May 31, 2026 (Cut-off Time). Audit fees paid to Deloitte were $1,071,000 for 2025 and $1,433,000 for 2024. Proxy voting options, quorum rules and vote thresholds for each proposal are described in the proxy materials.
NewAmsterdam Pharma Co N.V. director Louis G. Lange reported open-market sales of a total of 44,619 Ordinary Shares on March 11, 2026. He sold 44,173 shares at a weighted average price of $30.41 per share and 446 shares at a weighted average price of $31.23 per share. After these sales, he directly owns 10,360 Ordinary Shares. The prices reflect multiple trades in ranges from $30.11 to $31.31 per share.
NewAmsterdam Pharma Company N.V. resale filing shows planned and recent transfers of Ordinary Shares. The filing lists a warrant exercise issuing 44,619 Ordinary Shares on 03/09/2026 for cash. It also records that The LG Lange III Trust sold 28,186 Ordinary Shares on 03/06/2026 for $828,849.41.
This Form 144 excerpt documents resale activity by a trust and a warrant-related issuance; cash‑flow treatment for proceeds beyond the warrant exercise is not detailed in the excerpt.
NewAmsterdam Pharma director Louis G. Lange reported a mix of warrant exercises and share sales. On March 9, 2026, he exercised warrants to acquire 44,619 Ordinary Shares at $11.50 per share, leaving him with 54,979 Ordinary Shares held directly.
Separately, on March 6, 2026, a trust associated with him, the LGLange III Trust DTD10, sold 28,186 Ordinary Shares in open-market transactions at a weighted average price of $29.41 per share, within a range of $29.03 to $29.68, and reported no remaining indirect holdings.
NewAmsterdam Pharma Co N.V. Chief Scientific Officer Johannes Jacob Pieter Kastelein, through Futurum B.V., exercised options for 300,000 Ordinary Shares at an exercise price of EUR 1.16392 and sold 300,000 shares in open-market transactions around $30 per share between March 5–9, 2026. The shares and options are held indirectly via Futurum and NAP PoolCo B.V. for his benefit, with the reporting person retaining sole voting and investment control.
NAMS submitted a Form 144 reporting proposed sales of Ordinary Shares through J.P. Morgan Securities LLC. The filing lists multiple lots acquired via RSU awards, purchases and option exercise on dates including 12/11/2025, 05/13/2025, 04/02/2025, 02/14/2024, 12/19/2023, and 06/07/2023, with lot sizes shown such as 68, 69, 3,102, 5,000, 9,787, and 10,000. The broker is listed as J.P. Morgan Securities LLC on Nasdaq.
NewAmsterdam Pharma Co N.V. CEO Michael H. Davidson reported an option exercise-and-sell transaction on March 2, 2026. He exercised options for 443,707 ordinary shares at EUR 1.16392 per share and sold 443,707 shares at $33.25 per share.
Following the transactions, Davidson held 174,144 ordinary shares directly, with 239,267 options remaining under the reported grant.
NewAmsterdam Pharma submitted a Form 144 notice reporting the proposed sale of 443,707 ordinary shares by option exercise on 03/02/2026 for cash on Nasdaq. The filing also lists recent sales by Michael Davidson totaling 318,145 shares across 01/07/2026–02/26/2026.